CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM106881
035-os BibID:(cikkazonosító)100040 (Scopus)85148085127 (WoS)000982550100001
Első szerző:Dundr, Pavel
Cím:Primary Mucinous Tumors of the Ovary : An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories / Dundr Pavel, Bártu Michaela, Bosse Tjalling, Bui Quang Hiep, Cibula David, Drozenová Jana, Fabian Pavel, Fadare Oluwole, Hausnerová Jitka, Hojny Jan, Hájková Nikola, Jaksa Radek, Laco Jan, Lax Sigurd F., Matej Radoslav, Méhes Gábor, Michálková Romana, Safanda Adam, Nemejcová Kristyna, Singh Naveena, Stolnicu Simona, Svajdler Marián, Zima Tomás, Struzinská Ivana, McCluggage W. Glenn
Dátum:2023
ISSN:0893-3952
Megjegyzések:Primary ovarian mucinous tumors represent a heterogeneous group of neoplasms, and their diagnosis may be challenging. We analyzed 124 primary ovarian mucinous tumors originally diagnosed as mucinous borderline tumors (MBTs) or mucinous carcinomas (MCs), with an emphasis on interobserver diagnostic agreement and the potential for diagnostic support by molecular profiling using a next-generation sequencing targeted panel of 727 DNA and 147 RNA genes. Fourteen experienced pathologists independently assigned a diagnosis from preset options, based on a review of a single digitized slide from each tumor. After excluding 1 outlier participant, there was a moderate agreement in diagnosing the 124 cases when divided into 3 categories (k= 0.524, for mucinous cystadenoma vs MBT vs MC). A perfect agreement for the distinction between mucinous cystadenoma/MBT as a combined category and MC was found in only 36.3% of the cases. Differentiating between MBTs and MCs with expansile invasion was particularly problematic. After a reclassification of the tumors into near-consensus diagnostic categories on the basis of the initial participant results, a comparison of molecular findings between the MBT and MC groups did not show major and unequivocal differences between MBTs and MCs or between MCs with expansile vs infiltrative pattern of invasion. In contrast, HER2 overexpression or amplification was found only in 5.3% of MBTs and in 35.3% of all MCs and in 45% of MCs with expansile invasion. Overall, HER2 alterations, including mutations, were found in 42.2% of MCs. KRAS mutations were found in 65.5% and PIK3CA mutations in 6% of MCs. In summary, although the diagnostic criteria are well-described, diagnostic agreement among our large group of experienced gynecologic pathologists was only moderate. Diagnostic categories showed a molecular overlap. Nonetheless, molecular profiling may prove to be therapeutically beneficial in advanced-stage, recurrent, or metastatic MCs.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Modern Pathology. - 36 : 1 (2023), p. 1-14. -
További szerzők:Bártủ, Michaela Bosse, Tjalling Bui, Quang Hiep Cibula, David Drozenová, Jana Fabian, Pavel Fadare, Oluwole Hausnerová, Jitka Hojny, Jan Hájková, Nikola Jaksa, Radek Laco, Jan Lax, Sigurd F. Matej, Radoslav Méhes Gábor (1966-) (patológus) Michálková, Romana Safanda, Adam Nĕmejcová, Kristýna Singh, Naveena Stolnicu, Simona Svajdler, Marián Zima Tomás Struzinská, Ivana McCluggage, W. Glenn
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM112827
035-os BibID:(scopus)85149153484 (wos)000941171800001
Első szerző:Nĕmejcová, Kristýna
Cím:A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors / Nemejcová Kristyna, Safanda Adam, Bártu Michaela Kendall, Michálková Romana, Drozenová Jana, Fabian Pavel, Hausnerová Jitka, Laco Jan, Matej Radoslav, Méhes Gábor, Skapa Petr, Struzinská Ivana, Dundr Pavel
Dátum:2023
ISSN:1746-1596
Megjegyzések:Background: We examined a large cohort of serous tubo-ovarian tumors with 26 immunohistochemical markers, with the aim to assess their value for differential diagnosis and prognosis. Methods: Immunohistochemical analyses with 26 immunomarkers were performed on 250 primary tubo-ovarian tumors including 114 high grade serous carcinomas (HGSC), 97 low grade serous carcinomas (LGSC), and 39 serous borderline tumors (micropapillary variant, mSBT). The associations of overall positivity with clinicopathological charac- teristics were evaluated using the chi-squared test or Fisher's Exact test. Results: We found significantly different expression of p53, p16, ER, PR, PTEN, PAX2, Mammaglobin, RB1, Cyclin E1, stathmin, LMP2, L1CAM, CD44, and Ki67 in HGSCs compared to LGSCs. No significant differences were found between LGSC and mSBT. None of the other included markers (PAX8, ARID1A, HNF1B, Napsin A, CDX2, SATB2, MUC4, BRG1, AMACR, TTF1, BCOR, NTRK) showed any differences between the investigated serous tumors. Regarding the prognosis, only PR and stathmin showed a statistically significant prognostic meaning in LGSCs, with better overall survival (OS) and recurrence-free survival (RFS) in cases positive for PR, and worse outcome (RFS) for stathmin. None of the study markers showed prognostic significance in HGSCs. Conclusion: We provided an extensive immunohistochemical analysis of serous ovarian/tubo-ovarian tumors. Although we found some differences in the expression of some markers in HGSCs compared to LGSCs, only p53, p16, and Ki67 seem to be useful in real diagnostic practice. We also suggested the best discriminative cut-off for Ki67 (10% of positive tumor cells) for distinguishing HGSC from LGSC. We found prognostic significance of PR and stathmin in LGSCs. Moreover, the high expression of stathmin could also be of predictive value in ovarian carcinomas as target specific anti-stathmin effectors are potential therapeutic targets.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Diagnostic Pathology. - 18 : 1 (2023), p. 1-12. -
További szerzők:Safanda, Adam Bártủ, Michaela Michálková, Romana Drozenová, Jana Fabian, Pavel Hausnerová, Jitka Laco, Jan Matej, Radoslav Méhes Gábor (1966-) (patológus) Škapa, Petr Struzinská, Ivana Dundr, Pavel
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM116533
035-os BibID:(scopus)85168619897 (wos)001063398000003
Első szerző:Safanda, Adam
Cím:Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors / Safanda Adam, Kendall Bártu Michaela, Michálková Romana, Struzinská Ivana, Drozenová Jana, Fabián Pavel, Hausnerová Jitka, Laco Jan, Matej Radoslav, Skapa Petr, Svajdler Marián, Spurková Zuzana, Méhes Gábor, Dundr Pavel, Nemejcová Kristyna
Dátum:2023
ISSN:0945-6317
Megjegyzések:Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy. We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs. The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance. The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Cancer
Immunohistochemistry
Ovarian tumors
PRAME
Megjelenés:Virchows Archiv. - 483 : 4 (2023), p. 509-516. -
További szerzők:Kendall Bártů, Michaela Michálková, Romana Struzinská, Ivana Drozenová, Jana Fabian, Pavel Hausnerová, Jitka Laco, Jan Matej, Radoslav Škapa, Petr Svajdler, Marián Špůrková, Zuzana Méhes Gábor (1966-) (patológus) Dundr, Pavel Nĕmejcová, Kristýna
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1